10.96 0.00 (0.00%)
After hours: 4:42PM EST
|Bid||10.69 x 1800|
|Ask||11.20 x 1100|
|Day's Range||10.72 - 10.96|
|52 Week Range||8.77 - 15.08|
|Beta (3Y Monthly)||0.64|
|PE Ratio (TTM)||44.37|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||18.58|
ChemoCentryx, Inc. and Vifor Fresenius Medical Care Renal Pharma Ltd., a company of Vifor Pharma Group, today announced that in light of the upcoming availability of data from the pivotal Phase III ADVOCATE trial – the largest controlled trial in active anti-neutrophil cytoplasmic antibody associated vasculitis (ANCA-associated vasculitis) – they have decided to withdraw the application for Conditional Marketing Authorization (CMA) of avacopan for the treatment of ANCA-associated vasculitis based on Phase II data. Efforts will now be exclusively directed to file integrated regulatory submissions in 2020 with the European Medicines Agency (EMA) and United States Food and Drug Administration (FDA) for full (unconditional) marketing approval, after the planned release of topline data from the Phase III ADVOCATE clinical trial anticipated already in the fourth quarter of 2019.
MOUNTAIN VIEW, Calif., Jan. 02, 2019 -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at.
-- Studies highlight CCX4503, a unique small molecule inhibitor of immune checkpoint molecules PD-1/PD-L1, demonstrates anti-tumor efficacy in vivo ---- Company’s studies also.
NEW YORK, Nov. 27, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
MOUNTAIN VIEW, Calif., Nov. 20, 2018 -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at.
ChemoCentryx (CCXI) delivered earnings and revenue surprises of 12.00% and -22.29%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
The Mountain View, California-based company said it had a loss of 22 cents per share. The results surpassed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment ...
ChemoCentryx (CCXI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Comparable sales were down 0.6 percent, while analysts expected a 0.3 percent increase. Kimbell Royalty Partners KRP stock dipped almost 6 percent in the extended session after the company announced a public offering of 3 million shares of common stock. ChemoCentryx CCXI shares fell as much as 12 percent in after-hours trading following an announcement that the biopharmaceutical company has commenced a public offering of $75 million worth of common stock.
Vifor Pharma Group acquires an additional 7,343,492 common shares of ChemoCentryx, Inc. (CCXI) from GlaxoSmithKline - an additional 14.6% stake in the company. As a result Vifor Pharma Group will hold a total of 21.2% of ChemoCentryx on completion of the transaction. The increased investment follows the establishment of a partnership with ChemoCentryx, which began in May 2016.
ChemoCentryx (CCXI) delivered earnings and revenue surprises of -27.27% and -11.02%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
The Mountain View, California-based company said it had a loss of 14 cents per share. The results missed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research ...